Resolution:Standard | High | Highest
GELNIQUE Gel 10% - Approved by FDA for the...
 
 
 
 
 
 
 

GELNIQUE Gel 10% - Approved by FDA for the Treatment of OAB

 
 
 

Video Details

Uploaded Mar. 5, 2009 by
newsinfusionnewsinfusion

For more info on this and other stories, visit www.newsinfusion.com Corona, CA, January 27, 2009 – Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has approved GELNIQUE™ (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The U.S. OAB market currently exceeds $1.8 billion annually and continues to grow each year. GELNIQUE will provide OAB patients with an effective and novel alternative to currently available oral treatment options. Because the active ingredient in GELNIQUE is delivered transdermally, it is not metabolized by the liver in the same way as orally administered oxybutynin. This results in a low level of side effects, such as dry mouth and constipation. GELNIQUE will be actively marketed to physicians, and Watson anticipates that the ...

Post your comment

  • user avatar

Showing 1 - 0 of 0 comments

Show hidden comments

    VoteBar 1.1